Trial Profile

A phase 3 study of Accrufer in inflammatory bowel disease (IBD) patients

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 02 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ferric maltol (Primary)
Indications Iron deficiency anaemia
Focus Registrational; Therapeutic Use
Sponsors Beijing Aosaikang Pharmaceutical

Most Recent Events

24 Apr 2025 According to a Shield Therapeutics media release, ASK pharma announced completion of the recruitment of adult patients with IBD and IDA in the Phase 3 confirmatory study, which is the final study required to support the filing of an NDA in China for the commercialisation of ACCRUFeR/ FeRACCRU. The Company expects the NDA to be filed with the Chinese National Medical Products Administration (NMPA) in 2025.
24 Apr 2025 Status changed from recruiting to active, no longer recruiting.
05 Jul 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com